NZ594556A - Carboxamide compounds and methods for using the same - Google Patents
Carboxamide compounds and methods for using the sameInfo
- Publication number
- NZ594556A NZ594556A NZ594556A NZ59455610A NZ594556A NZ 594556 A NZ594556 A NZ 594556A NZ 594556 A NZ594556 A NZ 594556A NZ 59455610 A NZ59455610 A NZ 59455610A NZ 594556 A NZ594556 A NZ 594556A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- methods
- same
- carboxamide compounds
- picolinamide
- Prior art date
Links
- -1 Carboxamide compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- DSJRNDLCRQFHAQ-DEOSSOPVSA-N 5-[4-(4-chlorophenyl)piperazine-1-carbonyl]-n-[(3s)-1-[(4-fluorophenyl)methyl]pyrrolidin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1C[C@@H](NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC2)C=2C=CC(Cl)=CC=2)CC1 DSJRNDLCRQFHAQ-DEOSSOPVSA-N 0.000 abstract 1
- UFGUSXMLWUVPQK-UHFFFAOYSA-N 5-[4-[(4-cyanophenyl)methyl]piperazine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC=3C=CC(=CC=3)C#N)CC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 UFGUSXMLWUVPQK-UHFFFAOYSA-N 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14798209P | 2009-01-28 | 2009-01-28 | |
| PCT/US2010/022411 WO2010088392A1 (en) | 2009-01-28 | 2010-01-28 | Carboxamide compounds and methods for using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594556A true NZ594556A (en) | 2013-11-29 |
Family
ID=42061132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ594556A NZ594556A (en) | 2009-01-28 | 2010-01-28 | Carboxamide compounds and methods for using the same |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8362235B2 (enExample) |
| EP (1) | EP2391616B1 (enExample) |
| JP (1) | JP5658688B2 (enExample) |
| KR (1) | KR101693061B1 (enExample) |
| CN (1) | CN102365275B (enExample) |
| AU (1) | AU2010208247B2 (enExample) |
| BR (1) | BRPI1007287B8 (enExample) |
| CA (1) | CA2750835C (enExample) |
| EA (1) | EA022083B1 (enExample) |
| ES (1) | ES2581678T3 (enExample) |
| IL (1) | IL214203A (enExample) |
| MX (1) | MX2011007639A (enExample) |
| NZ (1) | NZ594556A (enExample) |
| SG (1) | SG172974A1 (enExample) |
| UA (1) | UA106600C2 (enExample) |
| WO (1) | WO2010088392A1 (enExample) |
| ZA (1) | ZA201105215B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722139C (en) | 2008-04-23 | 2017-04-11 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| CA2806341C (en) * | 2010-07-29 | 2020-03-24 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| US9409884B2 (en) | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| WO2015048547A2 (en) * | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| WO2015046595A1 (ja) | 2013-09-30 | 2015-04-02 | 国立大学法人東京大学 | アディポネクチン受容体活性化化合物 |
| US11597715B2 (en) | 2018-01-11 | 2023-03-07 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| US12194023B2 (en) | 2018-11-29 | 2025-01-14 | The Research Foundation For The State University Of New York | Compositions and methods for modular control of bioorthogonal ligation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| KR100579792B1 (ko) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | 신규 2,5-피리딘디카복실산 유도체 |
| EP1319001A1 (en) * | 2000-09-22 | 2003-06-18 | Smithkline Beecham Plc | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
| TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| CA2634235A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| EP1932834B1 (en) | 2006-12-11 | 2011-04-27 | The Genetics Company, Inc. | Aromatic 1,4-DI-Carboxylamides and their use |
| EP2079694B1 (en) * | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| GB0706793D0 (en) * | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| KR101573091B1 (ko) | 2007-11-16 | 2015-11-30 | 리겔 파마슈티칼스, 인크. | 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물 |
| CA2707047C (en) * | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| CA2722139C (en) * | 2008-04-23 | 2017-04-11 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
-
2010
- 2010-01-28 NZ NZ594556A patent/NZ594556A/xx not_active IP Right Cessation
- 2010-01-28 WO PCT/US2010/022411 patent/WO2010088392A1/en not_active Ceased
- 2010-01-28 AU AU2010208247A patent/AU2010208247B2/en not_active Ceased
- 2010-01-28 KR KR1020117019811A patent/KR101693061B1/ko not_active Expired - Fee Related
- 2010-01-28 EP EP10703206.2A patent/EP2391616B1/en active Active
- 2010-01-28 SG SG2011050861A patent/SG172974A1/en unknown
- 2010-01-28 BR BRPI1007287A patent/BRPI1007287B8/pt not_active IP Right Cessation
- 2010-01-28 ES ES10703206.2T patent/ES2581678T3/es active Active
- 2010-01-28 EA EA201170979A patent/EA022083B1/ru not_active IP Right Cessation
- 2010-01-28 MX MX2011007639A patent/MX2011007639A/es active IP Right Grant
- 2010-01-28 JP JP2011548297A patent/JP5658688B2/ja not_active Expired - Fee Related
- 2010-01-28 UA UAA201110421A patent/UA106600C2/uk unknown
- 2010-01-28 US US12/695,861 patent/US8362235B2/en not_active Expired - Fee Related
- 2010-01-28 CA CA2750835A patent/CA2750835C/en active Active
- 2010-01-28 CN CN201080015415.6A patent/CN102365275B/zh not_active Expired - Fee Related
-
2011
- 2011-07-14 ZA ZA2011/05215A patent/ZA201105215B/en unknown
- 2011-07-20 IL IL214203A patent/IL214203A/en active IP Right Grant
-
2012
- 2012-12-27 US US13/728,374 patent/US8846600B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UA106600C2 (uk) | 2014-09-25 |
| ZA201105215B (en) | 2012-09-26 |
| CN102365275B (zh) | 2014-09-24 |
| EA201170979A1 (ru) | 2012-02-28 |
| BRPI1007287B1 (pt) | 2021-03-09 |
| US20130131078A1 (en) | 2013-05-23 |
| HK1164860A1 (zh) | 2012-09-28 |
| WO2010088392A1 (en) | 2010-08-05 |
| KR101693061B1 (ko) | 2017-01-04 |
| KR20110119755A (ko) | 2011-11-02 |
| MX2011007639A (es) | 2011-09-15 |
| AU2010208247B2 (en) | 2015-06-18 |
| CA2750835A1 (en) | 2010-08-05 |
| AU2010208247A1 (en) | 2011-08-11 |
| ES2581678T3 (es) | 2016-09-06 |
| US20100190802A1 (en) | 2010-07-29 |
| SG172974A1 (en) | 2011-08-29 |
| BRPI1007287B8 (pt) | 2021-05-25 |
| US8362235B2 (en) | 2013-01-29 |
| US8846600B2 (en) | 2014-09-30 |
| IL214203A (en) | 2015-01-29 |
| IL214203A0 (en) | 2011-08-31 |
| EA022083B1 (ru) | 2015-10-30 |
| EP2391616B1 (en) | 2016-03-30 |
| CN102365275A (zh) | 2012-02-29 |
| JP5658688B2 (ja) | 2015-01-28 |
| JP2012516349A (ja) | 2012-07-19 |
| EP2391616A1 (en) | 2011-12-07 |
| CA2750835C (en) | 2018-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594556A (en) | Carboxamide compounds and methods for using the same | |
| NZ596467A (en) | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators | |
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| NO20084874L (no) | Piendinylsubstituerte pyrrolidinoner som hemmere av 11-beta-hydroksysteroiddehydrogenase 1 | |
| GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
| NZ592062A (en) | Akt and p70 s6 kinase inhibitors and their use in the treatment of glioblastoma multiforme | |
| NZ594765A (en) | Anthelmintic agents and their use | |
| NO20084923L (no) | N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer | |
| CR9875A (es) | Inhibidores de dipeptidilo peptidasa para tratar diabetes | |
| PL2029529T3 (pl) | PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1 | |
| WO2006012226A3 (en) | N-substituted piperidines and their use as pharmaceuticals | |
| MX2010006238A (es) | Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico. | |
| IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
| CL2012001221A1 (es) | Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras. | |
| NZ597125A (en) | Gpr119 agonists | |
| NZ595073A (en) | Proline derivatives as cathepsin inhibitors | |
| WO2007137066A3 (en) | HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | |
| HRP20120969T1 (hr) | Spoj azola | |
| NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
| UA100364C2 (xx) | Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів | |
| MX2009013272A (es) | Formas amorfas estabilzadas de mesilato de imatinib. | |
| PE20140409A1 (es) | Derivados de 4-(5-ciano-pirazol-1-il)-piperidina como moduladores de gpr 119 | |
| TW200800954A (en) | Novel crystal modifications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JAN 2017 BY COMPUTER PACKAGES INC Effective date: 20140328 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2018 BY COMPUTER PACKAGES INC Effective date: 20161231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2019 BY COMPUTER PACKAGES INC Effective date: 20180103 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2020 BY COMPUTER PACKAGES INC Effective date: 20190101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2021 BY COMPUTER PACKAGES INC Effective date: 20191231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20210119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20211230 |
|
| LAPS | Patent lapsed |